Glenmark launches Corona virus drug

Medication firm Glenmark Pharmaceuticals said it has launched antiviral medication Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate Covid-19 at a cost of about Rs 103 for every tablet.

The medication will be accessible as a 200 mg tablet at a most extreme retail value (MRP) of Rs 3,500 for a segment of 34 tablets, Glenmark Pharmaceuticals said. FabiFlu is the first oral favipiravir-endorsed medicine in Quite a while for the treatment of Covid-19, it said in an announcement.

It is a remedy based prescription, with a suggested portion being 1,800 mg twice day by day on the very first moment, trailed by 800 mg twice day by day up to day 14, it included. The tablets are being created by the organization at its Baddi office in Himachal Pradesh. The medication will be accessible both through clinics and the retail channel.